Answers are grounded in this paper and cite their sources.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are recognized as a single disease entity with distinct phenotypic manifestations, characterized by predominant peripheral blood (PB) involvement in CLL and nodal and/or splenic disease in SLL1-3. This article explores the historically divergent approaches taken to treat CLL and SLL, highlights recent advances in understanding their shared biology, and advocates for a unified approach to real-world management and clinical trial eligibility for both conditions.
No takes yet. Share an insight, caveat, or question.
Peters et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: